Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $107.00 price target on Cytokinetics (NASDAQ: CYTK).The analyst commented, "Our ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE